[Research Progress of Lung Cancer Vaccines]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2023 Nov 20

PMID 37985155

Authors

Hao Fan

Xiangwei Ge

Xin Zhou

Yao Li

An Wang

Yi Hu

Affiliations

Soon will be listed here.

Abstract

With the development of medical technology, tumor vaccines as a novel precise immunotherapy approach have gradually received attention in clinical applications. Against the backdrop of the global corona virus disease 2019 (COVID-19) outbreak, vaccine technology has further advanced. Depending on the types of antigens, tumor vaccines can be divided into whole-cell vaccines, peptide vaccines, messenger ribonucleic acid (mRNA) vaccines, recombinant virus vaccines, etc. Although some tumor vaccines have been marketed and achieved certain therapeutic effects, the results of tumor vaccines in clinical trials have been unsatisfactory in the past period. With the maturation of next-generation sequencing (NGS) technology and the continuous development of bioinformatics, dynamic monitoring of the entire process of tumor subpopulation development has become a reality, which has laid a solid foundation for personalized, neoantigen-centered therapeutic tumor vaccines. This article reviews the recent developments of tumor vaccines of different types, starts with lung cancer and summarizes the achievements of tumor vaccines in clinical applications, and provides an outlook for the future development of antigen-centered tumor vaccines. .

References

Madan R, Karzai F, Donahue R, Al-Harthy M, Bilusic M, Rosner I . Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. J Immunother Cancer. 2021; 9(3). PMC: 7934713. DOI: 10.1136/jitc-2020-001556. View

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View

Vreeland T, Litton J, Qiao N, Philips A, Alatrash G, Hale D . Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol. 2018; 192:6-13. PMC: 5988975. DOI: 10.1016/j.clim.2018.03.010. View

Richters M, Xia H, Campbell K, Gillanders W, Griffith O, Griffith M . Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 2019; 11(1):56. PMC: 6714459. DOI: 10.1186/s13073-019-0666-2. View

Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L . Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol. 2021; 12:650486. PMC: 8137829. DOI: 10.3389/fimmu.2021.650486. View

Thess A, Grund S, Mui B, Hope M, Baumhof P, Fotin-Mleczek M . Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol Ther. 2015; 23(9):1456-64. PMC: 4817881. DOI: 10.1038/mt.2015.103. View

Patel J, Lee J, Carbone D, Wagner H, Shanker A, de Aquino M . Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clin Lung Cancer. 2020; 21(6):520-526. PMC: 7606595. DOI: 10.1016/j.cllc.2020.06.007. View

Rodriguez P, Popa X, Martinez O, Mendoza S, Santiesteban E, Crespo T . A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2016; 22(15):3782-90. DOI: 10.1158/1078-0432.CCR-15-0855. View

Sultan H, Kumai T, Nagato T, Wu J, Salazar A, Celis E . The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunol Immunother. 2019; 68(3):455-466. PMC: 6428613. DOI: 10.1007/s00262-018-02294-5. View

10.

To K, Cho W . An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov. 2021; 16(11):1307-1317. DOI: 10.1080/17460441.2021.1935859. View

11.

Giaccone G, Bazhenova L, Nemunaitis J, Tan M, Juhasz E, Ramlau R . A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015; 51(16):2321-9. DOI: 10.1016/j.ejca.2015.07.035. View

12.

Anderson K, Erick T, Chen M, Daley H, Campbell M, Colson Y . The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. Breast Cancer Res Treat. 2022; 194(1):65-78. PMC: 9046531. DOI: 10.1007/s10549-022-06562-y. View

13.

Guo Z, Lu B, Guo Z, Giehl E, Feist M, Dai E . Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019; 7(1):6. PMC: 6325819. DOI: 10.1186/s40425-018-0495-7. View

14.

Nemunaitis J, Dillman R, Schwarzenberger P, Senzer N, Cunningham C, Cutler J . Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006; 24(29):4721-30. DOI: 10.1200/JCO.2005.05.5335. View

15.

Finn O . The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2017; 18(3):183-194. DOI: 10.1038/nri.2017.140. View

16.

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

17.

Arlen P, Skarupa L, Pazdur M, Seetharam M, Tsang K, Grosenbach D . Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007; 178(4 Pt 1):1515-20. DOI: 10.1016/j.juro.2007.05.117. View

18.

Abdelaziz M, Ossmann S, Kaufmann A, Leitner J, Steinberger P, Willimsky G . Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation. Front Immunol. 2019; 10:1776. PMC: 6682651. DOI: 10.3389/fimmu.2019.01776. View

19.

Chick R, Clifton G, Hale D, Vreeland T, Hickerson A, Kemp Bohan P . Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021; 225:108679. DOI: 10.1016/j.clim.2021.108679. View

20.

Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L . Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023; 8(1):9. PMC: 9816309. DOI: 10.1038/s41392-022-01270-x. View